Last reviewed · How we verify
Elena N.Parovichnikova — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
2 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| R-BL-M-04 + auto-SCT | R-BL-M-04 + auto-SCT | phase 3 | Oncology | |||
| R-BL-M-04 | R-BL-M-04 | phase 3 | small molecule | unknown | unknown |
Therapeutic area mix
- Oncology · 1
- unknown · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Ahn-Gook Pharmaceuticals Co.,Ltd · 1 shared drug class
- Avalo Therapeutics, Inc. · 1 shared drug class
- Chang Gung Memorial Hospital · 1 shared drug class
- ChemRar Research and Development Institute, LLC · 1 shared drug class
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 1 shared drug class
- Cipla BioTec Pvt. Ltd. · 1 shared drug class
- Daewon Pharmaceutical Co., Ltd. · 1 shared drug class
- AJU Pharm Co., Ltd. · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Elena N.Parovichnikova:
- Elena N.Parovichnikova pipeline updates — RSS
- Elena N.Parovichnikova pipeline updates — Atom
- Elena N.Parovichnikova pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Elena N.Parovichnikova — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/elena-n-parovichnikova. Accessed 2026-05-17.